Clinical Trial Search

Primary: Number of Participants With Visit to a Cardiology Specialist From Cohort — 283 Participants

Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min

Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943

Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio

Primary: Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent) — 32.4; 31.6 % 10 yr Risk

Primary: Change in FMD% — -0.06; -0.11; -0.06 FMD percent — p=0.864

Primary: Change From Baseline of Total Cholesterol After 90 Days — -0.57; -1.09 mmol/L — p=0.042

Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L

Primary: Major Cardiovascular Disease Event — 3182; 527 Cardiovascular disease event

Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039

Primary: Cardiovascular Disease Risk Factors — 3; 4; 5; 7 participants

Primary: New Participation in MOVE! (Among Women Aged 65 and Older) — 1.09 Odds Ratio — p=.003

Primary: Occurrence of First Hospitalisation or Hospital Outpatient Clinic Visit for Atrial Fibrillation or Flutter (AF) — 246; 725 Events

Primary: Endothelial Function — 0.13; -0.04 reactive hypermia index

Primary: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript — 8.6; 2.8 Fold Change

Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation

Primary: Number of Participants With Hypertension — 532 participants

Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)

Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331

Primary: Vascular Endothelial Function — -195.9; -6.181; -5.629 %*min

Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Vascular Endothelial Function — -307; -34.8; -36.8; -110 %*min

Primary: Changes in Body Weight From Baseline — -1.88; -1.77 Kilograms

Primary: Change in East Boston Memory Test Scores From Baseline to 24 Weeks, 48 Weeks, and 72 Weeks — 0.03; -0.02; 0.01; 0.05 score on a scale — p=.409

Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days

Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement

Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005

Primary: Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c…

Primary: Number of Participants With Type 2 Diabetes (T2D) Who Had Prescription Changes in Concordance With SSCVD Results — 45; 13; 8; 35 Participants